Mabcampath (alemtuzumab) - Risk Of Haemophagocytic Lymphohistiocytosis, Stroke (including Ischaemic And Haemorrhagic Stroke), And Glomerulonephritis

MabCampath Recall Summary MabCampath (alemtuzumab) is being recalled in Canada because it carries risks of three serious conditions: haemophagocytic lymphohistiocytosis (a blood disorder), stroke (both types), and glomerulonephritis (kidney inflammation). The drug was distributed across Canada. This recall applies to patients currently taking or considering this medication.

Reason

Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2020-06-22

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/c97a4937-8eaa-4b0c-96ad-eaa98f0b1586